Autolus Therapeutics plc ADR (NASDAQ: AUTL) kicked off on Tuesday, up 4.48% from the previous trading day, before settling in for the closing price of $1.34. Over the past 52 weeks, AUTL has traded in a range of $1.11-$5.25.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 251.43%. While this was happening, its average annual earnings per share was recorded -4.85%. With a float of $240.32 million, this company’s outstanding shares have now reached $266.13 million.
The extent of productivity of a business whose workforce counts for 647 workers is very important to gauge. In terms of profitability, gross margin is 61.23%, operating margin of -2273.11%, and the pretax margin is -2165.37%.
Autolus Therapeutics plc ADR (AUTL) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Autolus Therapeutics plc ADR is 9.70%, while institutional ownership is 54.57%. The most recent insider transaction that took place on Sep 16 ’24, was worth 2,955,674.
Autolus Therapeutics plc ADR (AUTL) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.25 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -4.85% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 23.49% during the next five years compared to 21.36% growth over the previous five years of trading.
Autolus Therapeutics plc ADR (NASDAQ: AUTL) Trading Performance Indicators
Take a look at Autolus Therapeutics plc ADR’s (AUTL) current performance indicators. Last quarter, stock had a quick ratio of 10.77. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 36.82.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.87, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -0.74 in one year’s time.
Technical Analysis of Autolus Therapeutics plc ADR (AUTL)
The latest stats from [Autolus Therapeutics plc ADR, AUTL] show that its last 5-days average volume of 2.83 million was superior to 1.41 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 53.34%. Additionally, its Average True Range was 0.15.
During the past 100 days, Autolus Therapeutics plc ADR’s (AUTL) raw stochastic average was set at 12.58%, which indicates a significant decrease from 49.58% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 127.08% in the past 14 days, which was higher than the 77.20% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.7589, while its 200-day Moving Average is $3.0580. Now, the first resistance to watch is $1.4533. This is followed by the second major resistance level at $1.5067. The third major resistance level sits at $1.5633. If the price goes on to break the first support level at $1.3433, it is likely to go to the next support level at $1.2867. Assuming the price breaks the second support level, the third support level stands at $1.2333.
Autolus Therapeutics plc ADR (NASDAQ: AUTL) Key Stats
The company with the Market Capitalisation of 372.57 million has total of 266,094K Shares Outstanding. Its annual sales at the moment are 10,120 K in contrast with the sum of -220,660 K annual income. Company’s last quarter sales were recorded 30 K and last quarter income was -27,610 K.
